Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.3606
-0.0058-1.58%
Volume:560.32K
Turnover:203.81K
Market Cap:33.13M
PE:-0.75
High:0.3790
Open:0.3790
Low:0.3597
Close:0.3664
52wk High:3.62
52wk Low:0.3470
Shares:91.88M
Float Shares:63.73M
Volume Ratio:0.75
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:0.87
PE(LYR):-0.95

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)

TIPRANKS
·
May 10

Context Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Context Therapeutics (CNTX) Gets a Buy from Guggenheim

TIPRANKS
·
May 07

Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)

TIPRANKS
·
May 07

Context Therapeutics Q1 net loss widens 90% to $8.68 million

Reuters
·
May 07

Context Therapeutics Q1 net loss widens on higher R&D costs

Reuters
·
May 07

Context Therapeutics - Cash and Cash Equivalents of $54.5 Mln as of March 31, 2026 Expected to Fund Operations Into Mid-2027

THOMSON REUTERS
·
May 07

Context Therapeutics Inc. Q1 Basic EPS USD -0.09

THOMSON REUTERS
·
May 07

Context Therapeutics settles governance lawsuit with mootness fee

TIPRANKS
·
May 02

Context Therapeutics litigation ends with $850,000 mootness fee paid by provider

Reuters
·
May 02

Context Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Apr 30

Context Therapeutics announces annual shareholder meeting

Reuters
·
Apr 18

Neogen names Jennifer Evans Stacey chief legal, compliance officer, board secretary

Reuters
·
Apr 08

JonesTrading Remains a Buy on Context Therapeutics (CNTX)

TIPRANKS
·
Apr 07

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)

TIPRANKS
·
Apr 02

Context Therapeutics Gains FDA Fast Track for CTIM-76

TIPRANKS
·
Apr 02

Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA

TIPRANKS
·
Apr 02

Context Therapeutics’ CTIM-76 wins FDA fast-track status for platinum-resistant ovarian cancer

Reuters
·
Apr 02

Context Therapeutics - Ctim-76 Phase 1a Trial Ongoing, Interim Data Expected June 2026

THOMSON REUTERS
·
Apr 02

Context Therapeutics Announces Ctim-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 02